Monday, 19 October 2020

Targeted therapy based on molecular profiling of malignant mesothelioma tumours is feasible

 Treatment recommendations from the recently held MAP 2020 Virtual Congress indicated that "molecular profiling demonstrated gender specific differences in gene expression" in patients with metastatic malignant mesothelioma.  The study, conducted at the Universitatsklinik fur Innere Medizin in Vienna, Austria determined that this form of targeted therapy varied according to gender, with more significant recommendations made for men vs. women "due to gender-specific differences in PDGRFA expression." 

To read more about this study, click here

Source mentioned: 

Taghizadeh H, Zöchbauer-Müller S, Mader RM, Müllauer L, Klikovits T, Bachleitner-Hofmann T, Hoda MA, Prager GW. Gender differences in molecular-guided therapy recommendations for metastatic malignant mesothelioma. Thorac Cancer. 2020 Jul;11(7):1979-1988. doi: 10.1111/1759-7714.13491. Epub 2020 May 21. PMID: 32438515; PMCID: PMC7327667.

No comments:

Post a Comment